Sugi Predict

Sugi Predict / Compounds / SCHEMBL25756890

SCHEMBL25756890

SCHEMBL25756890

O=c1[nH]cnc2c1c(I)cn2CC1CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACACB O00763 1/20 0.38
▸ KDM4A O75164 2/20 0.35
▸ KDM4B O94953 2/20 0.35
▸ KDM5C P41229 2/20 0.35
▸ KDM5B Q9UGL1 2/20 0.35
▸ SRC P12931 1/20 0.35
▸ LMNA P02545 3/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ ALB P02768 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ HPRT1 P00492 3/20 0.33
▸ KDM2A Q9Y2K7 1/20 0.32
▸ KDM3A Q9Y4C1 1/20 0.32
▸ MPO P05164 1/20 0.32
▸ TPO P07202 1/20 0.32
▸ SIGMAR1 Q99720 1/20 0.32
▸ MAPT P10636 3/20 0.32
▸ GAA P10253 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ CYP11B2 P19099 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21246839 0.76 KDM4E (0.39) SRCLMNAALDH1A1HPRT1MAPT
SCHEMBL398112 0.74 DYRK3 (0.54) ACACBSRCMAPK1
SCHEMBL25065700 0.72 ABL1 (0.39) SRCALDH1A1GAAHTT
SCHEMBL22086527 0.72 ABL1 (0.39) SRCALDH1A1GAAHTT
SCHEMBL21246829 0.72 SMN1; SMN2 (0.39) SRCLMNAALDH1A1HPRT1MAPT
SCHEMBL400113 0.71 ADK (0.44) ACACBSRC
SCHEMBL20971325 0.71 HPRT1 (0.45) ACACBKDM4AKDM4BKDM5CKDM5B
SCHEMBL15265574 0.71 ALDH1A1 (0.44) SRCLMNAALDH1A1MAPTGAA
SCHEMBL16236821 0.69 DYRK3 (0.52) ACACBSRC
SCHEMBL16236133 0.69 MAP4K4 (0.51) ACACBSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 — — US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 — — US disclosed
EP-4448514-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF Lynk Pharmaceuticals Co. Ltd. (CN) 2024-10-23 — — EP disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 — — US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 — — WO disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 ACACB 1956/4885KDM4A 323/4885KDM4B 301/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 ACACB 1956/4885KDM4A 323/4885KDM4B 301/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 ACACB 1956/4885KDM4A 323/4885KDM4B 301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.